General
Novo Nordisk names new CEO amid share price slump and concerns over Wegovy, Ozempic sales
Danish pharmaceutical giant Novo Nordisk, known for its weight-loss drugs Wegovy and Ozempic, has named Maziar Mike Doustdar as its new chief executive, relying on an experienced company insider to make up ground lost to market rivals.
Mr Doustdar’s appointment came on Tuesday after the abrupt…
Continue Reading
-
Noosa News24 hours agoAustralia Post reintroduces weekend deliveries for Christmas parcel rush
-
Business23 hours agoWhy this investing expert is calling time on NAB shares
-
General19 hours agoFederal government funding extends cohealth GP services until July 2026
-
Noosa News17 hours agoSunshine Coast Airport receives green light for major upgrade opening doors to growth jobs and tourism across the region